Bio‑Techne (TECH) director adds 1,640 shares, 3,777 options

Bio‑Techne (TECH) director reported equity changes on 10/30/2025.

Accepted by SEC EDGAR 11/03/2025 - 05:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Bio‑Techne (TECH) director reported equity changes on 10/30/2025. The filing shows an acquisition of 1,640 shares of Common Stock at $0, bringing direct holdings to 15,411 shares. It also reports a new grant of 3,777 stock options with an exercise price of $60.96 and an expiration on 10/30/2035. According to the note, this option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.

Insider Trade Summary

Grant/Award: 5,417 shares

Grant/Award 2 txns

Insider KEEGAN JOSEPH D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	3,777	$0.00	$0.00
Grant/Award	Common Stock	1,640	$0.00	$0.00
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 51,381 contracts for 47,604 underlying shares (Direct); Common Stock — 15,411 shares (Direct)

Footnotes (1)

1. F1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bio‑Techne (TECH) disclose in this Form 4?

A director acquired 1,640 Common Stock at $0 and received 3,777 stock options on 10/30/2025.

How many Bio‑Techne shares does the reporting person own after the transaction?

Direct beneficial ownership is 15,411 shares following the reported transaction.

What are the key terms of the newly granted stock options for TECH?

The new grant covers 3,777 options at an exercise price of $60.96, expiring on 10/30/2035.

When do the new Bio‑Techne options vest?

Per the note, they vest on the earlier of the one year anniversary of the grant date (10/30/2025) or Bio‑Techne’s 2026 annual meeting of shareholders.

What is the reporting person’s relationship to Bio‑Techne (TECH)?

The reporting person is a Director of Bio‑Techne.

Was the transaction reported as part of a 10b5‑1 plan?

The form includes the standard 10b5‑1 checkbox language; the excerpt does not indicate it was checked.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KEEGAN JOSEPH D

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		A		1,640	A	$0	15,411	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D
Stock Options (Right to Buy)	$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D
Stock Options (Right to Buy)	$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D
Stock Options (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Options (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Options (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Options (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Options (Right to Buy)	$68.37							10/24/2025	10/24/2034	Common Stock	3,511		3,511	D
Stock Options (Right to Buy)	$60.96	10/30/2025		A		3,777		(1)	10/30/2035	Common Stock	3,777	$0	3,777	D

Explanation of Responses:

1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

	/s/ Andrew Nick as Attorney-in-Fact for Joseph D. Keegan pursuant to Power of Attorney previously filed	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.